Phio Pharmaceuticals

Yahoo Finance • 3 months ago

Phio Pharma stock maintains buy rating as cancer trial advances

Investing.com - H.C. Wainwright has reiterated its buy rating and $14.00 price target on Phio Pharma (NASDAQ:PHIO), representing significant upside from the current price of $2.17. According to InvestingPro data, the stock has shown strong... Full story

Yahoo Finance • 3 months ago

Phio's PH-762 shows positive safety profile in fourth cohort trial

MARLBOROUGH, MASSACHUSETTS - Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a $10.6 million market cap biotechnology company whose stock has gained over 22% year-to-date, announced Wednesday that its Safety Monitoring Committee has recommended... Full story

Yahoo Finance • 2 years ago

Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective i... Full story

Yahoo Finance • 2 years ago

Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas

MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective i... Full story

Yahoo Finance • 2 years ago

Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control

MARLBOROUGH, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective i... Full story

Yahoo Finance • 2 years ago

Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

MARLBOROUGH, Mass., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective i... Full story

Yahoo Finance • 2 years ago

Phio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL™ Compound PH-894

--Preclinical data shows melanoma cells treated with PH-894 makes them more recognizable to immune cells, increasing potential for elimination --Preclinical data demonstrates the effectiveness of PH-894 as an antitumor cytotoxic agent (di... Full story

Yahoo Finance • 2 years ago

Phio CEO to Speak at Wainwright Conference in New York in September

MARLBOROUGH, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in kil... Full story

Yahoo Finance • 2 years ago

Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute

MARLBOROUGH, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective i... Full story